VEGF as a biomarker for metastatic uveal melanoma in humans

Current Eye Research

Volumn 36, Issue 4, 2011, Pages 386-390

  Barak, Vivian ^a   Pe'er, Jacob ^a   Kalickman, Inna ^a   Frenkel, Shahar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Metastasis; Serum; Tumor markers; Uveal melanoma; VEGF

Indexed keywords

TUMOR MARKER; VASCULOTROPIN;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UVEA MELANOMA;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MELANOMA; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952760563     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.534573     Document Type: Article

References (16)

1. Scotto J, Fraumeni Jr. JF, Lee JA. Melanomas of the eye and other noncutaneous sites: Epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group, Report No. 26. Arch Ophthalmol. 2005;123:1639-1643. (Pubitemid 41785095)
3. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol. 2006;124:1684-1693.
4. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh). 1982;60:161-182.
5. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol. 2001;119: 951-965.
6. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:1042-1046.
7. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: A pilot study. Invest Ophthalmol Vis Sci. 2006;47:802-806. (Pubitemid 46768309)
8. Barak V, Frenkel S, Kalickman I, et al. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27:1897-1900. (Pubitemid 46954694)
9. Sahin A, Kiratli H, Tezel GG, et al. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas. Ophthalmic Res. 2007;39:40-44. (Pubitemid 46095916)
10. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. 2006;124:1428-1434. (Pubitemid 44537143)
11. Lin AY, Maniotis AJ, Valyi-Nagy K, et al. Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch Pathol Lab Med. 2005;129:884-892. (Pubitemid 40934307)
12. El Filali M, Missotten GS, Maat W, et al. Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 2009 Dec 30. [Epub ahead of print].
13. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131. (Pubitemid 34791084)
14. Rennel E, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250-1257. (Pubitemid 351481687)
15. Rennel ES, Varey AH, Churchill AJ, et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer. 2009;101:1183-1193.
16. Karen Hendler, Jacob Pe'er, Igor Kaiserman, Ronen Baruch, Inna Kalickman, Vivian Barak, Shahar Frenkel A. Comparison with serum biomarkers in metastatic uveal melanoma, Anticancer Research, 2011 (in press).